Histological margin assessment for breast ductal carcinoma in situ:: precision and implications

被引:35
作者
Sigal-Zafrani, B
Lewis, JS
Clough, KB
Vincent-Salomon, A
Fourquet, A
Meunier, M
Falcou, MC
Sastre-Garau, X
机构
[1] Inst Curie, Dept Pathol, F-75248 Paris, France
[2] Inst Curie, Dept Surg, F-75248 Paris, France
[3] Inst Curie, Dept Radiotherapy, F-75248 Paris, France
[4] Inst Curie, Dept Radiol, F-75248 Paris, France
[5] Inst Curie, Dept Biostat, F-75248 Paris, France
关键词
ductal carcinoma in situ; lumpectomy; margin; residual disease; histopathology; classification;
D O I
10.1038/modpathol.3800019
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Local recurrence after lumpectomy for ductal carcinoma in situ ( DCIS) is a major concern and is related to residual disease in the breast. We studied the predictive value of lumpectomy margins for residual DCIS and compared our results and pathological processing techniques with those published in the literature. Margin status was determined for 89 patients with screen-detected DCIS who had lumpectomy and re-excision, for the presence and extent of residual disease. Margin width was defined as the narrowest distance between tumor and any inked margin or, where margins were positive, classified into focal involvement (<1 mm of the inked surface involved), minimal ( ≥1<15 mm) and extensive (greater than or equal to15 mm). The amount of residual tumor was quantified according to the number of ducts involved with tumor: small ( fewer than 10 ducts) or large ( 10 or more ducts) residuum. The initial margin status was a significant predictor for the presence of residual tumor in re-excision specimens ( P = 0.006). There was residual tumor in 44 and 45% of close non-involved (>1 and less than or equal to1 mm width) margins, 67% of focally, 71% of moderately and 94% of extensively positive margins. The pathologic tumor size was also a predictor for the presence of residual tumor with 27, 68 and 74% of lesions measuring less than or equal to10, 11 - 25, >25 mm, respectively, showing residual disease. The presence of residual tumor was not significantly related to age, mammographic appearance, nuclear grade or intraductal necrosis. The initial margin status was found to predict for the amount of residual tumor. With careful margin assessment, margin status after lumpectomy for DCIS can be used to predict for the presence and amount of residual tumor in the breast and is a guide to further management decisions. A standard for margin status reporting and pathological processing of screen- detected DCIS in situ lesions will help in the interpretation of data from different institutions.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 46 条
[1]   Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ [J].
Bijker, N ;
Peterse, JL ;
Duchateau, L ;
Robanus-Maandag, EC ;
Bosch, CAJ ;
Duval, C ;
Pilotti, S ;
van de Vijver, MJ .
BRITISH JOURNAL OF CANCER, 2001, 84 (04) :539-544
[2]   Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853 [J].
Bijker, N ;
Peterse, JL ;
Duchateau, L ;
Julien, JP ;
Fentiman, IS ;
Duval, C ;
Di Palma, S ;
Simony-Lafontaine, J ;
de Mascarel, I ;
van de Vijver, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2263-2271
[3]  
Chan KC, 2001, CANCER, V91, P9, DOI 10.1002/1097-0142(20010101)91:1<9::AID-CNCR2>3.0.CO
[4]  
2-E
[5]   Relationship between the size and margin status of ductal carcinoma in situ of the breast and residual disease [J].
Cheng, L ;
AlKaisi, NK ;
Gordon, NH ;
Liu, AY ;
Gebrail, F ;
Shenk, RR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (18) :1356-1360
[6]   Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program [J].
Ernster, VL ;
Barclay, J ;
Kerlikowske, K ;
Wilkie, H ;
Ballard-Barbash, R .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (07) :953-958
[7]   Incidence of and treatment for ductal carcinoma in situ of the breast [J].
Ernster, VL ;
Barclay, J ;
Kerlikowske, K ;
Grady, D ;
Henderson, IC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (12) :913-918
[8]   Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from national surgical adjuvant breast and bowel project B-17 [J].
Fisher, B ;
Dignam, J ;
Wolmark, N ;
Mamounas, E ;
Costantino, J ;
Poller, W ;
Fisher, ER ;
Wickerham, DL ;
Deutsch, M ;
Margolese, R ;
Dimitrov, N ;
Kavanah, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :441-452
[9]  
FISHER ER, 1995, CANCER-AM CANCER SOC, V75, P1310, DOI 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO
[10]  
2-G